This information is intended for use by health professionals
Selsun Shampoo 2.5%
Each 100 ml of suspension contains 2.5 g of Selenium Sulphide Ph. Eur.
Smooth, pale yellow to beige uniform suspension.
In the management of simple dandruff and seborrhoeic dermatitis of the scalp
Apply topically to the scalp.
Adults and the elderly:
After thoroughly wetting the hair massage Selsun in to form a lather. Rinse after 2 to 3 minutes.
Usage should be twice a week for the next two weeks to control the condition. After this initial course of treatment Selsun should not be used more often than necessary.
Children aged 5 – 14 years:
As for adults.
Children under 5 years of age:
Hypersensitivity to any of the ingredients.
Do not allow contact with broken or severely inflamed skin.
For external use only. Keep out of eyes; if Selsun gets into the eyes, wash thoroughly with cold water.
Do not leave the shampoo in contact with the hair or skin for more than the recommended duration as irritation, burning sensation or blistering may occur and do not use more often than recommended (see Section 4.2).
Selsun is not to be ingested.
In the event of accidental ingestion, take all appropriate measures immediately.
Selsun must not be applied to or on infected or broken skin as this may cause systemic absorption of the selenium sulfide
If the hair has been damaged by chemical substances (like dyeing or bleaching products or as a result of a permanent wave or relaxing treatment) or if the hair is grey or white, discoloration of the hair may occur. In order to avoid discoloration of the hair it must be thoroughly rinsed immediately after use
Selsun should be very thoroughly rinsed from the hair before dyeing, tinting, or permanent waving the hair. It should not be applied for a period of two days before or after any of these procedures.
Gold, silver and other metallic jewelry should be removed prior to use of Selsun, since discoloration of the metals may occur.
There are no adequate data from the use of selenium sulphide in pregnant women. Animal studies are insufficient with respect to effects on pregnancy, foetal development and postnatal development.
Avoid during pregnancy and breastfeeding.
No studies on the effects on the ability to drive or use machines have been performed.
Immune system disorder:
Hypersensitivity, rash and urticarial
Skin and subcutaneous tissue disorders:
Irritation and sensitization, sometimes described as a burning sensation, Blistering can occur, especially if the shampoo is kept in contact with hair or skin for longer than the recommended duration.
Alopecia can occur.
Hair color changes may occur; this can be avoided or minimized by thorough washing of the hair after treatment.
Seborrhea (oiliness of hair and scalp) or application site dryness may occur.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
If ingested, vomiting should be provoked and general supportive measures given.
Selenium sulphide appears to have a cytostatic effect on cells of the epidermis and follicular epithelium, thus reducing corneocyte production. Selsun acts as an antiseborrhoeic agent which effectively controls itching and scaling dandruff. It has activity against certain dermatophytes including Pityrosporum orbiculare, the organism causing pityriasis versicolor (tinea versicolor).
No additional preclinical information, relevant to the indication, is presented.
Bentonite, titanium dioxide, citric acid, sodium dihydrogen phosphate dihydrate, glyceryl monoricinoleate S, monoethanolamine lauryl sulphate, Empigen BB, perfume, sodium chloride, sodium hydroxide for pH adjustment, purified water.
Do not store above 25°C.
High density polyethylene bottles fitted with wadless caps, containing 50, 100 or 150ml.
Opella Healthcare UK Limited, trading as Sanofi
410 Thames Valley Park Drive
Date of first authorisation: 11 October 1989
Date of renewal of the authorisation: 30 July 2001